Sweden · Delayed Price · Currency is SEK Biosergen AB Statistics
Total Valuation
Biosergen AB has a market cap or net worth of SEK 11.74 million. The enterprise value is -3.63 million.
| Market Cap | 11.74M |
| Enterprise Value | -3.63M |
Important Dates
The next confirmed earnings date is Tuesday, August 18, 2026.
| Earnings Date | Aug 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biosergen AB has 2.35 million shares outstanding. The number of shares has decreased by -2.13% in one year.
| Current Share Class | 2.35M |
| Shares Outstanding | 2.35M |
| Shares Change (YoY) | -2.13% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 42.01% |
| Float | 851,564 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.00 |
| P/TBV Ratio | 1.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.46
| Current Ratio | 2.46 |
| Quick Ratio | 2.42 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9,509.75 |
Financial Efficiency
Return on equity (ROE) is -126.77% and return on invested capital (ROIC) is -79.29%.
| Return on Equity (ROE) | -126.77% |
| Return on Assets (ROA) | -65.27% |
| Return on Invested Capital (ROIC) | -79.29% |
| Return on Capital Employed (ROCE) | -323.38% |
| Weighted Average Cost of Capital (WACC) | 4.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -38.01M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.91% in the last 52 weeks. The beta is -0.04, so Biosergen AB's price volatility has been lower than the market average.
| Beta (5Y) | -0.04 |
| 52-Week Price Change | -88.91% |
| 50-Day Moving Average | 8.56 |
| 200-Day Moving Average | 33.30 |
| Relative Strength Index (RSI) | 19.71 |
| Average Volume (20 Days) | 6,613 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.04M |
| Pretax Income | -38.01M |
| Net Income | -38.01M |
| EBITDA | n/a |
| EBIT | -38.04M |
| Earnings Per Share (EPS) | -16.19 |
Balance Sheet
The company has 15.37 million in cash and n/a in debt, with a net cash position of 15.37 million or 6.54 per share.
| Cash & Cash Equivalents | 15.37M |
| Total Debt | n/a |
| Net Cash | 15.37M |
| Net Cash Per Share | 6.54 |
| Equity (Book Value) | 11.76M |
| Book Value Per Share | 5.01 |
| Working Capital | 11.76M |
Cash Flow
| Operating Cash Flow | -36.81M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biosergen AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.13% |
| Shareholder Yield | 2.13% |
| Earnings Yield | -323.76% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 1, 2025. It was a reverse split with a ratio of 0.01.
| Last Split Date | Dec 1, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |